leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   807 Trials   807 Trials   14372 News 


«12...4950515253545556575859...235236»
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Journal:  Tumor tropic delivery of FU.FA@NSs using mesenchymal stem cells for synergistic chemo-photodynamic therapy of colorectal cancer. (Pubmed Central) -  May 4, 2023   
    FU.FA@NSs released from MSCs were effectively taken up by CT26 cells via a clathrin-mediated endocytosis pathway and distributed their drug depots in a pH, HO, and UVA-stimulated fashion. Therefore, the cell-based biomimetic drug delivery platform formulated in the current study could be considered a promising strategy for targeted chemo-photodynamic therapy of colorectal cancer.
  • ||||||||||  RENAL SAFETY OF FLOT REGIMEN FOR GASTROESOPHAGEAL CANCER (Focussed Oral Room 1) -  May 4, 2023 - Abstract #ERAEDTA2023ERA_EDTA_1168;    
    Background and Aims: Currently, peri-operative docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil (FLOT) chemotherapy is the gold standard treatment for patients with locally advanced gastric cancer (LAGC), who undergo peri-operative chemotherapy and surgery. According to our results, the pre-operative FLOT regimen seems to have a negligible impact on renal function with very low rate of renal toxicity suggesting the possibility to extend its use even in patient with advanced CKD.
  • ||||||||||  gevokizumab (VPM087) / Novartis
    Trial completion date, Combination therapy, Metastases:  Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers (clinicaltrials.gov) -  May 3, 2023   
    P1,  N=168, Active, not recruiting, 
    According to our results, the pre-operative FLOT regimen seems to have a negligible impact on renal function with very low rate of renal toxicity suggesting the possibility to extend its use even in patient with advanced CKD. Trial completion date: Jan 2025 --> Oct 2024
  • ||||||||||  5-fluorouracil / Generic mfg.
    Clinical, Journal, Metastases:  Prognostic significance of mucinous histology in left?sided metastatic colorectal cancers with wild?type RAS and evaluation of backbone chemotherapy regimens. (Pubmed Central) -  May 1, 2023   
    This is a retrospective multicenter study of mCRC treated with first line anti-EGFR combined 5-fluorouracil based chemotherapy (CT)...When considering backbone CT regimens, in multivariate analyses, mucinous histology was an independent prognostic factor for OS in both for mFOLFOX6 (HR: 1.92, P=0.04) and FOLFIRI (HR: 2.04, P=0.04) groups and was associated with poor PFS in only mFOLFOX6 (HR: 3.86, P<0.001) group...Moreover, lower PFS of MCAC patients was revealed in only mFOLFOX6 group and this finding may be a valuable issue for the future research. However, considering all analyses, the present results did not indicate a special benefit of any backbone CT regimen for MCAC patients.
  • ||||||||||  Clinical guideline, Review, Journal, PD(L)-1 Biomarker:  A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights. (Pubmed Central) -  May 1, 2023   
    In addition to regorafenib, apatinib, camrelizumab and tislelizumab are added as the second-line systemic therapies for patients who progressed on sorafenib. Updates in the 2022 Barcelona Clinic Liver Cancer (BCLC) guidelines and Japanese Society of Hepatology (JSH) consensus statement are also introduced and compared with the 2022 Chinese guidelines.
  • ||||||||||  5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
    Journal:  Development and validation of prognostic nomograms for large hepatocellular carcinoma after HAIC. (Pubmed Central) -  Apr 28, 2023   
    In this large collaboration, we established two nomogram models to estimate the prognosis and evaluate the survival benefits with different HAIC combination therapy. It could help physicians in decision-making before HAIC and comprehensive treatment for large HCC patients in clinical practice and future trials.
  • ||||||||||  MK-1084 / Merck (MSD)
    Enrollment change, Trial completion date, Trial primary completion date, Monotherapy:  A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001) (clinicaltrials.gov) -  Apr 27, 2023   
    P1,  N=450, Recruiting, 
    Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023 N=264 --> 450 | Trial completion date: Feb 2026 --> Aug 2026 | Trial primary completion date: Feb 2026 --> Aug 2026
  • ||||||||||  New concept infusion pump with an anticancer drug exposure prevention function. () -  Apr 26, 2023 - Abstract #ASCO2023ASCO_5925;    
    Our newly developed infusion pump with an anticancer drug exposure prevention function may help enable the next generation of cancer drug exposure prevention measures. Support: Japan Agency for Medical Research and Development, Medical Innovation Project, Development and Commercialization Project (Adoption No.: 21he0122019j000).
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    The smart options of induction therapy for locally advanced betel-nuts related HNSCC in Taiwan. () -  Apr 26, 2023 - Abstract #ASCO2023ASCO_5705;    
    Flexible chemotherapy backbones, such as TP/DP-HDFL(weekly docetaxel or paclitaxel with cisplatin and 24-hr high dose 5-fluorouracil/leucovorin infusion), might produce acceptable response rates with less toxicity. Bio(EGFR or VEGFR-targeting)-chemotherapy or Bio-chemoimmunotherapy has brought encouraging induction response with favorable toxicity profiles to conversion surgery or definite CCRT.
  • ||||||||||  Components of total cost of care in real-world patients with mPDAC who received first-line FOLFIRINOX or Gem/Abrax. () -  Apr 26, 2023 - Abstract #ASCO2023ASCO_5249;    
    Among Medicare Fee-For-Service patients with mPDAC, patients receiving FOLFIRINOX (FFX) or Gemcitabine/Abraxane (Gem/Abrax) as a first-line therapy incurred similar costs of care overall, with different distributions across service categories. While therapy costs were lower among patients receiving generic FFX than those receiving branded Gem/Abrax, higher costs from supportive therapies offset those differences.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Dosing patterns and treatment patterns in real-world patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who received FOLFIRINOX in the first line. () -  Apr 26, 2023 - Abstract #ASCO2023ASCO_5227;    
    A sequence strategy introducing a nal-IRI-based regimen at later lines may be feasible in selected APC patients previously treated with conventional IRI, given the limited therapeutic options. Background: While FOLFIRINOX (FFX) demonstrated a significant overall and progression-free survival benefit vs. gemcitabine in the PRODIGE 4/ACCORD 11 trial among previously untreated patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC), treatment with FFX was associated with a higher rate of grade 3/4 adverse events (AEs)...The median number of cycles was 5 (IQR: 3